Cat. No.: HY-B0434

Ribavirin

(Synonyms: Ribasphere)

56 Cited Publications

Customer Review

Based on 56 publication(s) in Google Scholar

Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

For research use only. We do not sell to patients.

Purity: 99.96%
CAS No.: 36791-04-5
Formula: C₈H₁₂N₄O₅
Molecular Weight:244.20

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Ribavirin Chemical Structure

CAS No.: 36791-04-5

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (56)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	3.18 μM Compound: RBV	Antiproliferative activity against human A-431 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
A549	CC₅₀	307 μM Compound: Ribavirin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30612844]
A549	CC₅₀	129.65 μM Compound: Ribavirin	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 32882419]
A549	CC₅₀	>50 μM Compound: Ribavirin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34273661]
A549	CC₅₀	7611.1 μM Compound: Ribavirin	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34425312]
A549	CC₅₀	>50 μM Compound: Ribavirin	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35306290]
ACHN	IC₅₀	>100 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma	10.1016/0960-894X(96)00216-8
B16-F10	IC₅₀	3.5 μM Compound: RBV	Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
BHK-21	EC₅₀	1.1 μM Compound: Ribavirin	Inhibition of West Nile virus VLP replicon in BHK21 cell line Inhibition of West Nile virus VLP replicon in BHK21 cell line	[PMID: 16539402]
BHK-21	EC₅₀	18 μM Compound: Ribavirin	Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line	[PMID: 16539402]
BHK-21	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	[PMID: 19482481]
BHK-21	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 25082514]
BHK-21	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	[PMID: 26443549]
BHK-21	CC₅₀	5.46 μM Compound: RBV	Cytotoxicity against hamster BHK-21 cells incubated for 4 days by MTS assay Cytotoxicity against hamster BHK-21 cells incubated for 4 days by MTS assay	[PMID: 36764470]
BJ	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay	[PMID: 28350454]
C6	IC₅₀	13.51 μM Compound: RBV	Antiproliferative activity against rat C6 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against rat C6 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
C8166	IC₅₀	>100 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1. Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1.	10.1016/0960-894X(96)00216-8
Caco-2	IC₅₀	34.5 μM Compound: RBV	Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
Calu-3	CC₅₀	160 μM Compound: Ribavirin	Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition incubated for 4 hrs by XTT assay	[PMID: 36965227]
CCRF-CEM	EC₅₀	>50 μM Compound: Ribavirin	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 22464686]
CCRF-CEM	EC₅₀	>50 μM Compound: Ribavirin	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 22464686]
CCRF-CEM	IC₅₀	1 μM Compound: Ribavirin	Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins	[PMID: 22555152]
CCRF-CEM	IC₅₀	63 μM Compound: Ribavirin	Cytostatic activity against human CEM/0 after 72 hrs by cell counting Cytostatic activity against human CEM/0 after 72 hrs by cell counting	[PMID: 22555152]
CCRF-CEM	EC₅₀	>50 μM Compound: Ribavirin	Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24312722]
CCRF-CEM	EC₅₀	>50 μM Compound: Ribavirin	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	[PMID: 24312722]
CCRF-CEM	IC₅₀	19 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell growth in CEM cell line Tested for inhibitory effect on RNA virus cell growth in CEM cell line	[PMID: 8246242]
CCRF-CEM	IC₅₀	19 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line	10.1016/0960-894X(96)00216-8
CCRF-SB	IC₅₀	>100 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line. Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line.	10.1016/0960-894X(96)00216-8
CHO	IC₅₀	622.5 μM Compound: ribavirin	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
CHO-K1	IC₅₀	50 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line. Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line.	10.1016/0960-894X(96)00216-8
DU-145	IC₅₀	>100 μM Compound: RBV	Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
E6SM	EC₅₀	0.005 μM Compound: Ribavirin	Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	320 μM Compound: Ribavirin	Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	320 μM Compound: Ribavirin	Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	40 μM Compound: Ribavirin	Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	65 μM Compound: Ribavirin	Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	>400 μg/mL Compound: Ribavirin	Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: Ribavirin	Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: Ribavirin	Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: Ribavirin	Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: Ribavirin	Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: Ribavirin	Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	48 μg/mL Compound: Ribavirin	Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	48 μg/mL Compound: Ribavirin	Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	80 μg/mL Compound: Ribavirin	Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle	[PMID: 12459010]
E6SM	EC₅₀	240 μg/mL Compound: ribavirin	Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
E6SM	EC₅₀	150 μg/mL Compound: ribavirin	Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	20 μg/mL Compound: ribavirin	Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	20 μg/mL Compound: ribavirin	Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	70 μg/mL Compound: ribavirin	Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	70 μg/mL Compound: ribavirin	Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17518459]
E6SM	EC₅₀	>400 μg/mL Compound: Ribavirin	Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	>400 μg/mL Compound: Ribavirin	Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	>400 μg/mL Compound: Ribavirin	Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	>400 μg/mL Compound: Ribavirin	Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	EC₅₀	48 μg/mL Compound: Ribavirin	Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
E6SM	CC₅₀	>400 μg/mL Compound: ribavirin	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells	[PMID: 8709116]
E6SM	EC₅₀	128 μM Compound: d	concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells	[PMID: 9748360]
E6SM	EC₅₀	192 μM Compound: d	concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells	[PMID: 9748360]
E6SM	EC₅₀	192 μM Compound: d	concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells	[PMID: 9748360]
E6SM	EC₅₀	960 μM Compound: d	concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells	[PMID: 9748360]
E6SM	EC₅₀	960 μM Compound: d	concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells	[PMID: 9748360]
Epithelial cell	EC₅₀	>1024.6 μM Compound: Ribavirin	Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells	[PMID: 12729645]
ESM	IC₅₀	>135 μg/mL Compound: ribavirin	Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line	[PMID: 8246242]
ESM	IC₅₀	>300 μg/mL Compound: ribavirin	Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line	[PMID: 8246242]
ESM	IC₅₀	>=350 μg/mL Compound: ribavirin	Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line	[PMID: 8246242]
ESM	IC₅₀	>=400 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell morphology in ESM cell line Tested for inhibitory effect on RNA virus cell morphology in ESM cell line	[PMID: 8246242]
ESM	IC₅₀	110 μg/mL Compound: ribavirin	Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line	[PMID: 8246242]
ESM	IC₅₀	45 μg/mL Compound: ribavirin	Tested for inhibitory effect on DNA virus VV in ESM cell line Tested for inhibitory effect on DNA virus VV in ESM cell line	[PMID: 8246242]
Fibroblast	CC₅₀	>200 μM Compound: Rib	Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 30365885]
Fibroblast	CC₅₀	>200 μM Compound: Rib	Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 32092589]
FM3A	IC₅₀	3.9 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell growth in FM3A cell line Tested for inhibitory effect on RNA virus cell growth in FM3A cell line	[PMID: 8246242]
HCT-116	EC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay	[PMID: 36518704]
HCT-116	EC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay	[PMID: 36518704]
HCT-116	EC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay	[PMID: 36518704]
HEK293	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24313730]
HEK293	EC₅₀	15 μM Compound: RBV	Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay	[PMID: 24313730]
HEK293	EC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay	[PMID: 36518704]
HEK-293T	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay	[PMID: 24785979]
HEK-293T	EC₅₀	24.9 μM Compound: RBV	Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay	[PMID: 24785979]
HEK-293T	CC₅₀	>250 μM Compound: RBV, Ribavirin	Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay	[PMID: 25856229]
HEK-293T	EC₅₀	18 μM Compound: RBV, Ribavirin	Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay	[PMID: 25856229]
HEK-293T	CC₅₀	>200 μM Compound: ribavirin	Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay	[PMID: 26288686]
HEK-293T	EC₅₀	8.4 μM Compound: ribavirin	Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay	[PMID: 26288686]
HEK-293T	EC₅₀	13.1 μM Compound: ribavirin	Antiviral activity against Chikungunya virus infected in HEK293T cells assessed as reduction of infectivity measured at 24 hrs postinfection by gaussia luciferase reporter gene assay Antiviral activity against Chikungunya virus infected in HEK293T cells assessed as reduction of infectivity measured at 24 hrs postinfection by gaussia luciferase reporter gene assay	[PMID: 26540338]
HEK-293T	EC₅₀	18.4 μM Compound: ribavirin	Antiviral activity against O'nyong-nyong virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis Antiviral activity against O'nyong-nyong virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	[PMID: 26540338]
HEK-293T	EC₅₀	20 μM Compound: ribavirin	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	[PMID: 26540338]
HEK-293T	EC₅₀	5.12 μM Compound: ribavirin	Antiviral activity against wild type Sindbis virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis Antiviral activity against wild type Sindbis virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	[PMID: 26540338]
HEK-293T	CC₅₀	>250 μM Compound: RBV; Ribavirin	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 26924568]
HEK-293T	EC₅₀	23.8 μM Compound: RBV; Ribavirin	Inhibition of Influenza A virus RdRp transfected in HEK293T cells at 24 hrs by dual luciferase reporter gene-based minireplicon assay Inhibition of Influenza A virus RdRp transfected in HEK293T cells at 24 hrs by dual luciferase reporter gene-based minireplicon assay	[PMID: 26924568]
HEK-293T	CC₅₀	>205 μM Compound: Ribavirin	Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation after 24 hrs by CCK8 assay Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation after 24 hrs by CCK8 assay	[PMID: 28314599]
HEK-293T	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay	[PMID: 28350454]
HEK-293T	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 30142611]
HEK-293T	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay	[PMID: 31734025]
HEK-293T	IC₅₀	15.36 μM Compound: Ribavirin	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human 293T cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human 293T cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay	[PMID: 32273213]
HEK-293T	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against human HEK293T cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 32805550]
HEK-293T	IC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HEK-293T cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay Cytotoxicity against human HEK-293T cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay	[PMID: 33571829]
HEK-293T	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HEK293T cells assessed as cell viability after 48 hrs by CCK-8 assay Cytotoxicity against human HEK293T cells assessed as cell viability after 48 hrs by CCK-8 assay	[PMID: 35304224]
HEK-293T	CC₅₀	>50 μM Compound: RBV	Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293T cells incubated for 48 hrs by MTT assay	[PMID: 39153334]
HEL	CC₅₀	>500 μM Compound: Ribavirin	Cytotoxicity against HEL cells Cytotoxicity against HEL cells	[PMID: 17181162]
HEL	EC₅₀	>500 μM Compound: Ribavirin	Antiviral activity against HSV2 in HEL cells Antiviral activity against HSV2 in HEL cells	[PMID: 17181162]
HEL	EC₅₀	>500 μM Compound: Ribavirin	Antiviral activity against vesicular somatitis virus in HEL cells Antiviral activity against vesicular somatitis virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	100 μM Compound: Ribavirin	Antiviral activity against vaccinia virus in HEL cells Antiviral activity against vaccinia virus in HEL cells	[PMID: 17181162]
HEL	EC₅₀	120 μg/mL Compound: ribavirin	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	>250 μM Compound: ribavirin	Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	>250 μM Compound: ribavirin	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	112 μM Compound: ribavirin	Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	125 μM Compound: ribavirin	Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	250 μM Compound: ribavirin	Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HEL	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	146 μg/mL Compound: ribavirin	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	125 μM Compound: Ribavirin	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	50 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	85 μM Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	112 μM Compound: 1	Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20207546]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	1 μg/mL Compound: Ribavirin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	10 μg/mL Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	2 μg/mL Compound: Ribavirin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	2 μg/mL Compound: Ribavirin	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against HEL cells after 3 days by coulter counter analysis Cytotoxicity against HEL cells after 3 days by coulter counter analysis	[PMID: 21232828]
HEL	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 21232828]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
HEL	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HEL	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL 299	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human HEL 299 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
HEL 299	IC₅₀	45 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line. Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line.	10.1016/0960-894X(96)00216-8
HeLa	EC₅₀	>320 μM Compound: Ribavirin	Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines	[PMID: 11495586]
HeLa	EC₅₀	1.5 μM Compound: Ribavirin	Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines	[PMID: 11495586]
HeLa	EC₅₀	1 mM Compound: Ribavirin	Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines	[PMID: 11495586]
HeLa	CC₅₀	300 μg/mL Compound: Rib	Cytotoxicity against human HeLa cells after 2 days by MTT assay Cytotoxicity against human HeLa cells after 2 days by MTT assay	[PMID: 12444692]
HeLa	CC₅₀	300 μg/mL Compound: Rib (Ribavirin)	Cytotoxicity against HeLa cells Cytotoxicity against HeLa cells	[PMID: 14505657]
HeLa	EC₅₀	14.41 μg/mL Compound: Rib (Ribavirin)	Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells	[PMID: 14505657]
HeLa	EC₅₀	181.36 μg/mL Compound: Rib (Ribavirin)	Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells	[PMID: 14505657]
HeLa	EC₅₀	20.94 μg/mL Compound: Rib (Ribavirin)	Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells	[PMID: 14505657]
HeLa	CC₅₀	>300 μg/mL Compound: ribavirin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 17046264]
HeLa	CC₅₀	>500 μM Compound: Ribavirin	Cytotoxicity against HeLa cells Cytotoxicity against HeLa cells	[PMID: 17181162]
HeLa	EC₅₀	>500 μM Compound: Ribavirin	Antiviral activity against Coxsackie B4 virus in HeLa cells Antiviral activity against Coxsackie B4 virus in HeLa cells	[PMID: 17181162]
HeLa	EC₅₀	12 μM Compound: Ribavirin	Antiviral activity against RSV in HeLa cells Antiviral activity against RSV in HeLa cells	[PMID: 17181162]
HeLa	EC₅₀	16 μg/mL Compound: ribavirin	Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HeLa	EC₅₀	48 μg/mL Compound: ribavirin	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HeLa	EC₅₀	80 μg/mL Compound: ribavirin	Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
HeLa	IC₅₀	2 μg/mL Compound: ribavirin	Antiviral activity against Respiratory syncytial virus in HeLa cells Antiviral activity against Respiratory syncytial virus in HeLa cells	[PMID: 17518459]
HeLa	IC₅₀	20 μg/mL Compound: ribavirin	Antiviral activity against Coxsackie virus B4 in HeLa cells Antiviral activity against Coxsackie virus B4 in HeLa cells	[PMID: 17518459]
HeLa	IC₅₀	20 μg/mL Compound: ribavirin	Antiviral activity against VSV in HeLa cells Antiviral activity against VSV in HeLa cells	[PMID: 17518459]
HeLa	EC₅₀	150 μM Compound: ribavirin	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
HeLa	EC₅₀	24 μg/mL Compound: ribavirin	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	24 μg/mL Compound: ribavirin	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	90 μg/mL Compound: ribavirin	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
HeLa	EC₅₀	10 μg/mL Compound: Ribavirin	Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HeLa	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HeLa	EC₅₀	29 μg/mL Compound: Ribavirin	Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HeLa	EC₅₀	10 μM Compound: ribavirin	Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HeLa	EC₅₀	22 μM Compound: ribavirin	Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HeLa	EC₅₀	50 μM Compound: ribavirin	Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
HeLa	CC₅₀	426 μg/mL Compound: Ribovirin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19374435]
HeLa	IC₅₀	20.3 μg/mL Compound: Ribovirin	Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay	[PMID: 19374435]
HeLa	EC₅₀	10 μg/mL Compound: ribavirin	Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HeLa	EC₅₀	146 μg/mL Compound: ribavirin	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HeLa	EC₅₀	29 μg/mL Compound: ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HeLa	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method	[PMID: 20034711]
HeLa	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method	[PMID: 20034711]
HeLa	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method	[PMID: 20034711]
HeLa	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HeLa	EC₅₀	30 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay	[PMID: 20034711]
HeLa	EC₅₀	30 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20034711]
HeLa	EC₅₀	19 μM Compound: 1	Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20207546]
HeLa	EC₅₀	22 μM Compound: 1	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20207546]
HeLa	CC₅₀	>250 μg/mL Compound: ribavirin	Cytotoxicity against human HeLa cells after 3 days by MTS assay Cytotoxicity against human HeLa cells after 3 days by MTS assay	[PMID: 20347509]
HeLa	EC₅₀	17.2 μM Compound: ribavirin	Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 20347509]
HeLa	EC₅₀	6.6 μM Compound: ribavirin	Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 20347509]
HeLa	EC₅₀	73.1 μM Compound: ribavirin	Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 20347509]
HeLa	EC₅₀	16 μg/mL Compound: Ribavirin	Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
HeLa	EC₅₀	48 μg/mL Compound: Ribavirin	Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
HeLa	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HeLa	EC₅₀	22 μg/mL Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HeLa	EC₅₀	22 μg/mL Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HeLa	CC₅₀	>250 μg/mL Compound: Ribavirin	Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay	[PMID: 20971531]
HeLa	EC₅₀	10 μg/mL Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
HeLa	EC₅₀	14 μg/mL Compound: Ribavirin	Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HeLa	EC₅₀	2.8 μg/mL Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HeLa	EC₅₀	3.6 μg/mL Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HeLa	EC₅₀	50 μg/mL Compound: Ribavirin	Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
HeLa	EC₅₀	6 μg/mL Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
HeLa	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis	[PMID: 21565516]
HeLa	EC₅₀	14.8 μM Compound: Ribavirin	Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HeLa	EC₅₀	3 μM Compound: Ribavirin	Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HeLa	EC₅₀	69 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
HeLa	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HeLa	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HeLa	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HeLa	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in HeLa cells Antiviral activity against Respiratory syncytial virus infected in HeLa cells	[PMID: 22464686]
HeLa	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in HeLa cells Antiviral activity against Coxsackie virus B4 infected in HeLa cells	[PMID: 22464686]
HeLa	EC₅₀	29 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in HeLa cells Antiviral activity against Vesicular stomatitis virus infected in HeLa cells	[PMID: 22464686]
HeLa	EC₅₀	112 μM Compound: ribavirin	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HeLa	EC₅₀	29 μM Compound: ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HeLa	EC₅₀	5 μM Compound: ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
HeLa	EC₅₀	22 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HeLa	EC₅₀	5 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HeLa	EC₅₀	5 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
HeLa	CC₅₀	>500 μg/mL Compound: Ribavirin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 23920438]
HeLa	EC₅₀	27.8 μg/mL Compound: Ribavirin	Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method	[PMID: 23920438]
HeLa	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HeLa	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HeLa	EC₅₀	29 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
HeLa	EC₅₀	17 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 24906510]
HeLa	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
HeLa	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
HeLa	EC₅₀	22 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
HeLa	EC₅₀	5.8 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
HeLa	EC₅₀	50 μM Compound: Ribavirin	Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
HeLa	EC₅₀	85 μM Compound: Ribavirin	Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
HeLa	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology	[PMID: 32214762]
HeLa	EC₅₀	12.1 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HeLa	EC₅₀	28.5 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HeLa	EC₅₀	4.6 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HeLa	IC₅₀	11.4 μM Compound: Ribavirin	Inhibitory concentration against respiratory syncytial virus in HeLa cells Inhibitory concentration against respiratory syncytial virus in HeLa cells	[PMID: 7658442]
HeLa	IC₅₀	>=400 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line	[PMID: 8246242]
HeLa	IC₅₀	14 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus VSV in HeLa cell line Tested for inhibitory effect on RNA virus VSV in HeLa cell line	[PMID: 8246242]
HeLa	IC₅₀	4 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus RSV in HeLa cell line Tested for inhibitory effect on RNA virus RSV in HeLa cell line	[PMID: 8246242]
HeLa	IC₅₀	70 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line	[PMID: 8246242]
HeLa	CC₅₀	>200 μg/mL Compound: ribavirin	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells	[PMID: 8709116]
HeLa	EC₅₀	192 μM Compound: d	concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells	[PMID: 9748360]
HeLa	EC₅₀	320 μM Compound: d	concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells	[PMID: 9748360]
HeLa	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Respiratory syncytial virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HeLa	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B4 infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human coxsackievirus B4 infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HeLa	EC₅₀	29 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vesicular stomatitis virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEp-2	IC₅₀	2.6 μg/mL Compound: ribavirin	Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect	[PMID: 11678648]
HEp-2	CC₅₀	62.5 μg/mL Compound: ribavirin	Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay	[PMID: 16724853]
HEp-2	IC₅₀	3 μg/mL Compound: ribavirin	Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect	[PMID: 16724853]
HEp-2	EC₅₀	11.5 μM Compound: Ribavirin	Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	[PMID: 17576833]
HEp-2	EC₅₀	13.3 μM Compound: Ribavirin	Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	16.8 μM Compound: Ribavirin	Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	17.6 μM Compound: Ribavirin	Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	19 μM Compound: Ribavirin	Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	20.7 μM Compound: Ribavirin	Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay	[PMID: 17576833]
HEp-2	EC₅₀	25.3 μM Compound: Ribavirin	Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA	[PMID: 17576833]
HEp-2	EC₅₀	29 μM Compound: Ribavirin	Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay	[PMID: 17576833]
HEp-2	IC₅₀	10.7 μM Compound: ribavirin	Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay	[PMID: 19267453]
HEp-2	IC₅₀	10.7 μM Compound: ribavirin	Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay	[PMID: 19267453]
HEp-2	CC₅₀	113.9 μM Compound: 1	Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay	[PMID: 23043370]
HEp-2	EC₅₀	28.4 μM Compound: 1	Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay	[PMID: 23043370]
HEp-2	IC₅₀	20.4 μM Compound: ribavirin	Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay	[PMID: 24882250]
HEp-2	IC₅₀	20 μM Compound: ribavirin	Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay	[PMID: 25420212]
HEp-2	CC₅₀	571.6 μg/mL Compound: Ribavirin	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 28858766]
HEp-2	CC₅₀	273.8 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	[PMID: 31734025]
HEp-2	EC₅₀	15.83 μM Compound: Ribavirin	Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells measured 24 to 72 hrs post infection by fluorescence assay Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells measured 24 to 72 hrs post infection by fluorescence assay	[PMID: 31734025]
HEp-2	IC₅₀	0.08 μM Compound: Ribavirin	Antiviral activity against RSV infected in human HEp-2 cells assessed as inhibition of viral induced cytopathic effect by CPE assay Antiviral activity against RSV infected in human HEp-2 cells assessed as inhibition of viral induced cytopathic effect by CPE assay	[PMID: 32937282]
HEp-2	CC₅₀	3039.67 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability after 48 hrs by MTS assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability after 48 hrs by MTS assay	[PMID: 33571829]
HEp-2	IC₅₀	17.33 μM Compound: Ribavirin	Antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells assessed as reduction in viral replication after 48 hrs by MTS assay Antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells assessed as reduction in viral replication after 48 hrs by MTS assay	[PMID: 33571829]
HEp-2	CC₅₀	250 μM Compound: Ribavirin	Cytotoxicity in human Hep2 cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity in human Hep2 cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
HEp-2	CC₅₀	418.21 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 60 hrs by MTT assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 60 hrs by MTT assay	[PMID: 34256126]
HEp-2	EC₅₀	18.53 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells incubated for 60 hrs by MTT assay Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells incubated for 60 hrs by MTT assay	[PMID: 34256126]
HEp-2	IC₅₀	19 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay	[PMID: 35729787]
HEp-2	CC₅₀	>1000 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability	[PMID: 35729787]
HEp-2	CC₅₀	95 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 6 days by CellTiter-Glo assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 6 days by CellTiter-Glo assay	[PMID: 36596229]
HEp-2	EC₅₀	5.4 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay	[PMID: 36596229]
HEp-2	CC₅₀	653.33 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 37859725]
HEp-2	EC₅₀	20.12 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect measured after 6 days by CellTiter-Glo assay	[PMID: 37859725]
HEp-2	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against HEp-2 cells Cytotoxicity against HEp-2 cells	[PMID: 38447084]
HEp-2	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human HEp-2 cells measured after 3 days by CellTiter 96 aqueous one solution assay (Rvb >100 microM) Cytotoxicity against human HEp-2 cells measured after 3 days by CellTiter 96 aqueous one solution assay (Rvb >100 microM)	[PMID: 38579352]
HEp-2	IC₅₀	10.6 μM Compound: Ribavirin	Antiviral activity against Human respiratory syncytial virus infected in human HEp-2 cells assessed as plaque reduction preincubated with cells 15 mins followed by viral infection for 2.5 hrs and measured after 3 days by crystal violet staining based micr Antiviral activity against Human respiratory syncytial virus infected in human HEp-2 cells assessed as plaque reduction preincubated with cells 15 mins followed by viral infection for 2.5 hrs and measured after 3 days by crystal violet staining based micr	[PMID: 38579352]
HEp-2	CC₅₀	386.3 μM Compound: Ribavirin	Cytotoxicity against Coxsackievirus B3 infected human Hep-2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against Coxsackievirus B3 infected human Hep-2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 38976838]
HEp-2	EC₅₀	1.8 μg/mL Compound: Ribavirin	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	2.2 μg/mL Compound: Ribavirin	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	EC₅₀	2.3 μg/mL Compound: Ribavirin	Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	25 μg/mL Compound: Ribavirin	Cytotoxicity against human Hep2 cells administered 3 hrs postinfection Cytotoxicity against human Hep2 cells administered 3 hrs postinfection	[PMID: 9599250]
HEp-2	IC₅₀	25 μg/mL Compound: Ribavirin	Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	35 μg/mL Compound: Ribavirin	Cytotoxicity against RSV long infected human Hep2 cells after 3 days Cytotoxicity against RSV long infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	1.8 μg/mL Compound: ribavirin	Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 9784173]
HepG2	CC₅₀	>500 μg/mL Compound: Ribavirin	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23920438]
HepG2	EC₅₀	22.3 μg/mL Compound: Ribavirin	Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method	[PMID: 23920438]
HepG2	CC₅₀	246.27 μM Compound: RBV	Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay	[PMID: 37722289]
Huh-5-2	CC₅₀	21 μg/mL Compound: Ribavirin	Cytotoxicity against human Huh-5-2 cells Cytotoxicity against human Huh-5-2 cells	[PMID: 18445526]
Huh-5-2	EC₅₀	7 μg/mL Compound: Ribavirin	Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay	[PMID: 18445526]
Huh-5-2	CC₅₀	86 μM Compound: ribavirin	Cytotoxicity against human HuH5.2 cells Cytotoxicity against human HuH5.2 cells	[PMID: 19170598]
Huh-7	IC₅₀	32 μM Compound: ribavirin	Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay	[PMID: 17556358]
Huh-7	IC₅₀	37 μM Compound: ribavirin	Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay	[PMID: 17556358]
Huh-7	IC₅₀	39 μM Compound: ribavirin	Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay	[PMID: 17556358]
Huh-7	IC₅₀	58 μM Compound: ribavirin	Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay	[PMID: 17556358]
Huh-7	CC₅₀	>200 μM Compound: Ribavirin	Cytotoxicity against Huh7 cells by XTT assay Cytotoxicity against Huh7 cells by XTT assay	[PMID: 17766124]
Huh-7	EC₅₀	54.8 μM Compound: Ribavirin	Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay	[PMID: 17766124]
Huh-7	EC₅₀	22 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	33 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	36 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	36 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	41 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	42 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	43 μM Compound: ribavirin	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	EC₅₀	58 μM Compound: ribavirin	Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay	[PMID: 17938182]
Huh-7	CC₅₀	1060 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells after3 days by MTT assay Cytotoxicity against human HuH7 cells after3 days by MTT assay	[PMID: 20337460]
Huh-7	EC₅₀	17.6 μM Compound: Ribavirin	Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay	[PMID: 20337460]
Huh-7	CC₅₀	177.94 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 20579888]
Huh-7	CC₅₀	32 μM Compound: RBV	Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay	[PMID: 22100256]
Huh-7	EC₅₀	14 μM Compound: RBV	Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay	[PMID: 22100256]
Huh-7	EC₅₀	20 μg/mL Compound: Ribavirin	Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis	[PMID: 22985854]
Huh-7	EC₅₀	81.9 μM Compound: Ribavirin	Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis	[PMID: 24485784]
Huh-7	CC₅₀	56.31 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay	[PMID: 24727241]
Huh-7	IC₅₀	12.61 μM Compound: Ribavirin	Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay	[PMID: 24727241]
Huh-7	CC₅₀	56 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay	[PMID: 25330401]
Huh-7	EC₅₀	12.6 μM Compound: Ribavirin	Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay	[PMID: 25330401]
Huh-7	CC₅₀	>30 μM Compound: Ribavirin	Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay	[PMID: 26428870]
Huh-7	CC₅₀	30.5 μM Compound: Ribavirin	Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 ass Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 ass	[PMID: 26428870]
Huh-7	EC₅₀	30.4 μM Compound: Ribavirin	Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs	[PMID: 26428870]
Huh-7	EC₅₀	33.5 μM Compound: Ribavirin	Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug admini Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug admini	[PMID: 26428870]
Huh-7	CC₅₀	>100 μM Compound: ribavirin	Cytotoxicity against mock-infected human Huh7.5 cells assessed as reduction in cell viability incubated for 5 hrs by MTT assay Cytotoxicity against mock-infected human Huh7.5 cells assessed as reduction in cell viability incubated for 5 hrs by MTT assay	[PMID: 26613291]
Huh-7	EC₅₀	16.3 μM Compound: ribavirin	Antiviral activity against recombinant HCV genotype 2a JFH1 infected in human Huh7 cells incubated for 5 hrs measured on day 3 post infection by luciferase reporter gene assay Antiviral activity against recombinant HCV genotype 2a JFH1 infected in human Huh7 cells incubated for 5 hrs measured on day 3 post infection by luciferase reporter gene assay	[PMID: 26613291]
Huh-7	CC₅₀	56.31 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 3 days by XTT method Cytotoxicity against human HuH7 cells assessed as growth inhibition after 3 days by XTT method	[PMID: 29031073]
Huh-7	IC₅₀	>200 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells after 3 days by MTT assay Cytotoxicity against human HuH7 cells after 3 days by MTT assay	[PMID: 30721061]
Huh-7	IC₅₀	53.7 μM Compound: RBV	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
Huh-7	CC₅₀	100 μM Compound: Ribavirin	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 32435411]
Huh-7	IC₅₀	4 μM Compound: Ribavirin	Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte	[PMID: 32435411]
Huh-7	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human Huh-7 cells incubated for 3 days by MTT assay Cytotoxicity against human Huh-7 cells incubated for 3 days by MTT assay	[PMID: 32787106]
Huh-7	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against human Huh-7 cells incubated for 72 hrs by Cell Titer-Glo luminescence assay Cytotoxicity against human Huh-7 cells incubated for 72 hrs by Cell Titer-Glo luminescence assay	[PMID: 32787106]
Huh-7	CC₅₀	200 μM Compound: Ribavirin	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay	[PMID: 34273661]
Huh-7	CC₅₀	512.8 μM Compound: Ribavirin	Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35306290]
Huh-7	CC₅₀	8.9 μM Compound: Ribavirin	Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against human Huh-7 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
Huh-7.5	CC₅₀	1654 μM Compound: RBV	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by MTS assay Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by MTS assay	[PMID: 35661850]
HUVEC	CC₅₀	>150 μM Compound: RBV	Cytotoxicity against HUVECs assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method Cytotoxicity against HUVECs assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method	[PMID: 38493729]
IGROV-1	IC₅₀	16 μg/mL Compound: RBV	Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay	[PMID: 31883488]
IGROV-1	IC₅₀	21 μg/mL Compound: RBV	Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay	[PMID: 31883488]
IGROV-1	IC₅₀	25 μg/mL Compound: RBV	Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay	[PMID: 31883488]
L1210	IC₅₀	1 μM Compound: Ribavirin	Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins	[PMID: 22555152]
L1210	IC₅₀	7.1 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell growth in L1210 cell line Tested for inhibitory effect on RNA virus cell growth in L1210 cell line	[PMID: 8246242]
L1210	IC₅₀	16.6 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line. Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line.	10.1016/0960-894X(96)00216-8
MDA-MB-231	IC₅₀	>100 μM Compound: RBV	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
MDA-MB-435	IC₅₀	38.3 μM Compound: RBV	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
MDCK	EC₅₀	3.7 μM Compound: Ribavirin	Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells	[PMID: 12729645]
MDCK	CC₅₀	>125 μg/mL Compound: ribavirin	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	CC₅₀	62.5 μg/mL Compound: ribavirin	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	2.6 μg/mL Compound: ribavirin	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	2.6 μg/mL Compound: ribavirin	Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	62.5 μg/mL Compound: ribavirin	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 15104496]
MDCK	IC₅₀	62.5 μg/mL Compound: ribavirin	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 15104496]
MDCK	CC₅₀	>2000 μg/mL Compound: ribavirin	Cytotoxicity in MDCK cells infected with influenza A H3N2 virus Cytotoxicity in MDCK cells infected with influenza A H3N2 virus	[PMID: 16183283]
MDCK	IC₅₀	3.73 μg/mL Compound: ribavirin	Antiviral activity against influenza A H3N2 virus in MDCK cells Antiviral activity against influenza A H3N2 virus in MDCK cells	[PMID: 16183283]
MDCK	CC₅₀	2336 μM Compound: ribavirin	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 17194832]
MDCK	EC₅₀	14.3 μM Compound: ribavirin	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	35.7 μM Compound: ribavirin	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	38.1 μM Compound: ribavirin	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	43 μM Compound: ribavirin	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	[PMID: 17194832]
MDCK	EC₅₀	8.68 μM Compound: ribavirin	Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay	[PMID: 17588747]
MDCK	IC₅₀	15.2 μM Compound: ribavirin	Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	164 μM Compound: ribavirin	Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	176 μM Compound: ribavirin	Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	5.04 μM Compound: ribavirin	Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	5.85 μM Compound: ribavirin	Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	7.01 μM Compound: ribavirin	Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	IC₅₀	96.2 μM Compound: ribavirin	Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay	[PMID: 17611105]
MDCK	CC₅₀	>500 mg/mL Compound: Ribavirin	Cytotoxicity against dog MDCK cells Cytotoxicity against dog MDCK cells	[PMID: 18160286]
MDCK	IC₅₀	2.06 mg/mL Compound: Ribavirin	Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect	[PMID: 18160286]
MDCK	IC₅₀	4.27 mg/mL Compound: Ribavirin	Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect	[PMID: 18160286]
MDCK	CC₅₀	>512 μM Compound: ribavirin	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 18640042]
MDCK	CC₅₀	>100 μM Compound: ribavirin	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay	[PMID: 18778942]
MDCK	IC₅₀	42.6 μM Compound: ribavirin	Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay	[PMID: 19267453]
MDCK	CC₅₀	>100 μM Compound: ribavirin	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 19281225]
MDCK	EC₅₀	4 μM Compound: ribavirin	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	4.8 μM Compound: ribavirin	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	8.1 μM Compound: ribavirin	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	8400 μM Compound: ribavirin	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	[PMID: 19281225]
MDCK	EC₅₀	9 μM Compound: ribavirin	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	EC₅₀	900 μM Compound: ribavirin	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	[PMID: 19281225]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method	[PMID: 20034711]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method	[PMID: 20034711]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method	[PMID: 20034711]
MDCK	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
MDCK	EC₅₀	9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
MDCK	EC₅₀	9 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
MDCK	EC₅₀	9 μM Compound: 1	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20207546]
MDCK	EC₅₀	9 μM Compound: 1	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20207546]
MDCK	EC₅₀	10.2 μM Compound: 3	Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	11.2 μM Compound: 3	Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	13.9 μM Compound: 3	Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	16.4 μM Compound: 3	Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	19.4 μM Compound: 3	Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	19.5 μM Compound: 3	Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	20.2 μM Compound: 3	Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	23.3 μM Compound: 3	Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	23.6 μM Compound: 3	Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	25.1 μM Compound: 3	Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	27.4 μM Compound: 3	Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	32.5 μM Compound: 3	Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	35.4 μM Compound: 3	Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	4.3 μM Compound: 3	Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	8.4 μM Compound: 3	Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	[PMID: 20231094]
MDCK	EC₅₀	9.4 μM Compound: 3	Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	[PMID: 20231094]
MDCK	IC₅₀	>1310 μM Compound: 3	Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay	[PMID: 20231094]
MDCK	EC₅₀	13.93 μM Compound: Ribavirin	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	19.67 μM Compound: Ribavirin	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc	[PMID: 20350949]
MDCK	EC₅₀	20.92 μM Compound: Ribavirin	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis	[PMID: 20350949]
MDCK	EC₅₀	25 μM Compound: Ribavirin	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana	[PMID: 20350949]
MDCK	EC₅₀	35.6 μM Compound: Ribavirin	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy	[PMID: 20350949]
MDCK	EC₅₀	4.92 μM Compound: Ribavirin	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	[PMID: 20350949]
MDCK	EC₅₀	46.7 μM Compound: Ribavirin	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral	[PMID: 20350949]
MDCK	CC₅₀	>100 μg/mL Compound: Ribavirin	Cytotoxicity against MDCK cells by MTS assay Cytotoxicity against MDCK cells by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	12.9 μg/mL Compound: Ribavirin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	6 μg/mL Compound: Ribavirin	Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	7.8 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	[PMID: 20724039]
MDCK	EC₅₀	9 μg/mL Compound: Ribavirin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	9 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	9 μg/mL Compound: Ribavirin	Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
MDCK	EC₅₀	8.7 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay	[PMID: 20805012]
MDCK	CC₅₀	>100 μg/mL Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as cell viability by MTS assay Cytotoxicity against MDCK cells assessed as cell viability by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	12 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	4.3 μg/mL Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	7 μg/mL Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	8.4 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
MDCK	EC₅₀	9 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	9 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	[PMID: 20971531]
MDCK	EC₅₀	12.5 μM Compound: Ribavirin	Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
MDCK	EC₅₀	7.3 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
MDCK	EC₅₀	9.8 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
MDCK	IC₅₀	100.8 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay	[PMID: 21879714]
MDCK	IC₅₀	1.9 μM Compound: RBV	Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs	[PMID: 22341943]
MDCK	IC₅₀	14.7 μM Compound: RBV	Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs	[PMID: 22341943]
MDCK	IC₅₀	3.9 μM Compound: RBV	Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs	[PMID: 22341943]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	4.8 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	5.6 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	6.7 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	[PMID: 22459876]
MDCK	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
MDCK	EC₅₀	2.3 μM Compound: Ribavirin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
MDCK	EC₅₀	4.5 μM Compound: Ribavirin	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
MDCK	EC₅₀	5.1 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
MDCK	IC₅₀	114.8 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs	[PMID: 22487178]
MDCK	IC₅₀	35.3 μM Compound: RBV	Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22824205]
MDCK	IC₅₀	45.5 μM Compound: RBV	Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22824205]
MDCK	IC₅₀	8.8 μM Compound: RBV	Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 22824205]
MDCK	ED₅₀	24.6 μM Compound: Ribavirin	Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method	[PMID: 23099095]
MDCK	EC₅₀	4.6 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
MDCK	EC₅₀	6 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
MDCK	EC₅₀	6.1 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23099097]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	0.094 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	0.14 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	8.4 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	8.5 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	[PMID: 23117173]
MDCK	EC₅₀	8.9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	8.9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	[PMID: 23117173]
MDCK	EC₅₀	6.8 μM Compound: Ribavirin	Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	8.9 μM Compound: Ribavirin	Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	EC₅₀	8.9 μM Compound: Ribavirin	Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	[PMID: 23149298]
MDCK	IC₅₀	24.6 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method	[PMID: 23411074]
MDCK	IC₅₀	87 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay	[PMID: 23758051]
MDCK	IC₅₀	0.41 μM Compound: RIBA	Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay	[PMID: 23806112]
MDCK	IC₅₀	20.2 μM Compound: RIBA	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay	[PMID: 23806112]
MDCK	CC₅₀	>323.5 μM Compound: Ribavirin	Cytotoxicity against MDCK cells Cytotoxicity against MDCK cells	[PMID: 23811085]
MDCK	EC₅₀	18.43 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	18.43 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	23.75 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	5.73 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	[PMID: 23811085]
MDCK	EC₅₀	1.1 μM Compound: ribavirin	Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	2.5 μM Compound: ribavirin	Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	EC₅₀	2.8 μM Compound: ribavirin	Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	[PMID: 23811093]
MDCK	IC₅₀	113.1 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay	[PMID: 23886345]
MDCK	EC₅₀	7.2 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
MDCK	EC₅₀	8.3 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
MDCK	EC₅₀	9.6 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
MDCK	IC₅₀	14 μM Compound: Ribavirin	Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs	[PMID: 24216089]
MDCK	EC₅₀	9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
MDCK	EC₅₀	9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
MDCK	EC₅₀	9 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 24313730]
MDCK	EC₅₀	11 μM Compound: RBV	Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	12 μM Compound: RBV	Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	17 μM Compound: RBV	Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	2 μM Compound: RBV	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	6 μM Compound: RBV	Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	6 μM Compound: RBV	Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	7 μM Compound: RBV	Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	EC₅₀	8 μM Compound: RBV	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	[PMID: 24313730]
MDCK	IC₅₀	84 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique	[PMID: 24495078]
MDCK	IC₅₀	131 μM Compound: ribavirin	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay	[PMID: 24499327]
MDCK	IC₅₀	1.92 μg/mL Compound: RBV	Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	IC₅₀	3.27 μg/mL Compound: RBV	Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay	[PMID: 24583605]
MDCK	IC₅₀	5.59 μg/mL Compound: RBV	Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	IC₅₀	6.5 μg/mL Compound: RBV	Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	IC₅₀	7.84 μg/mL Compound: RBV	Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	[PMID: 24583605]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 24785979]
MDCK	EC₅₀	15.6 μM Compound: RBV	Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay	[PMID: 24785979]
MDCK	CC₅₀	>=20 μM Compound: ribavirin	Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 24900429]
MDCK	EC₅₀	10 μM Compound: ribavirin	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	7 μM Compound: ribavirin	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	[PMID: 24900429]
MDCK	EC₅₀	7.6 μM Compound: ribavirin	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	7.7 μM Compound: ribavirin	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	8 μM Compound: ribavirin	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	8.1 μM Compound: ribavirin	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	[PMID: 24900429]
MDCK	EC₅₀	8.2 μM Compound: ribavirin	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	[PMID: 24900429]
MDCK	EC₅₀	8.7 μM Compound: ribavirin	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	8.8 μM Compound: ribavirin	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	EC₅₀	8.8 μM Compound: ribavirin	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	[PMID: 24900429]
MDCK	IC₅₀	101 μM Compound: Ribavirin	Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay	[PMID: 24967847]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	11 μM Compound: Ribavirin	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	12 μM Compound: Ribavirin	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	21 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	6.8 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	6.8 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	EC₅₀	7.3 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	8.2 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	[PMID: 24974341]
MDCK	EC₅₀	8.9 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	[PMID: 24974341]
MDCK	CC₅₀	>200 μM Compound: RBV	Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay	[PMID: 25681711]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells after 72 hrs by MTS assay Cytotoxicity against MDCK cells after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	12 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	12 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	3.4 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	EC₅₀	8.9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	[PMID: 25752526]
MDCK	EC₅₀	9 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	[PMID: 25752526]
MDCK	CC₅₀	>250 μM Compound: RBV, Ribavirin	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay	[PMID: 25856229]
MDCK	EC₅₀	8 μM Compound: RBV, Ribavirin	Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay	[PMID: 25856229]
MDCK	IC₅₀	115 μM Compound: Ribavirin	Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay	[PMID: 26046820]
MDCK	CC₅₀	100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as inhibition of cell viability by colorimetric formazan-based MTS assay Cytotoxicity against MDCK cells assessed as inhibition of cell viability by colorimetric formazan-based MTS assay	[PMID: 26114811]
MDCK	IC₅₀	185.9 μM Compound: ribavirin	Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay	[PMID: 26114936]
MDCK	IC₅₀	5.86 μM Compound: RBV	Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption	[PMID: 26132528]
MDCK	CC₅₀	>100 μM Compound: ribavirin	Cytotoxicity against MDCK cells relative to control Cytotoxicity against MDCK cells relative to control	[PMID: 26260336]
MDCK	IC₅₀	9 μM Compound: ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay	[PMID: 26260336]
MDCK	CC₅₀	>200 μM Compound: ribavirin	Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay	[PMID: 26288686]
MDCK	EC₅₀	6.8 μM Compound: ribavirin	Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis	[PMID: 26288686]
MDCK	CC₅₀	>320 μg/mL Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay	[PMID: 26291036]
MDCK	CC₅₀	>320 μg/mL Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as cell viability by visual assay Cytotoxicity against MDCK cells assessed as cell viability by visual assay	[PMID: 26291036]
MDCK	EC₅₀	16 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay	[PMID: 26291036]
MDCK	EC₅₀	24 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay	[PMID: 26291036]
MDCK	CC₅₀	>200 μM Compound: RBV	Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	1.05 μM Compound: RBV	Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	1.43 μM Compound: RBV	Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	3.56 μM Compound: RBV	Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	EC₅₀	4.28 μM Compound: RBV	Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	[PMID: 26686929]
MDCK	IC₅₀	87.7 μg/mL Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 A3/JINGKE/30/95 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs Antiviral activity against Influenza A virus H3N2 A3/JINGKE/30/95 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs	[PMID: 26791013]
MDCK	CC₅₀	>250 μM Compound: RBV; Ribavirin	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 26924568]
MDCK	EC₅₀	12.8 μM Compound: RBV; Ribavirin	Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay	[PMID: 26924568]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	EC₅₀	7.5 μM Compound: Ribavirin	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay	[PMID: 27112451]
MDCK	EC₅₀	8.7 μM Compound: Ribavirin	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect	[PMID: 27112451]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	[PMID: 28477572]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28666191]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay	[PMID: 29220568]
MDCK	CC₅₀	>2130 μM Compound: Ribavirin	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 29716780]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay	[PMID: 29886325]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	[PMID: 29906392]
MDCK	CC₅₀	1365.5 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by crystal violet staining based method Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by crystal violet staining based method	[PMID: 30033162]
MDCK	CC₅₀	>2000 μM Compound: Ribavirin	Cytotoxicity against MDCK cells after 48 hrs by MTT assay Cytotoxicity against MDCK cells after 48 hrs by MTT assay	[PMID: 30108810]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 30142611]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay	[PMID: 30170320]
MDCK	CC₅₀	>2130 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30746065]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured on day 5 by Celltiter-Glo luminescence assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured on day 5 by Celltiter-Glo luminescence assay	[PMID: 30852083]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by alamar blue assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by alamar blue assay	[PMID: 31053507]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	[PMID: 31586832]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay	[PMID: 31753804]
MDCK	EC₅₀	4.6 μM Compound: Ribavirin	Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay	[PMID: 31753804]
MDCK	EC₅₀	8.4 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method	[PMID: 31753804]
MDCK	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as change in cellular morphology Cytotoxicity against MDCK cells assessed as change in cellular morphology	[PMID: 32214762]
MDCK	EC₅₀	11.5 μM Compound: Ribavirin	Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	6.8 μM Compound: Ribavirin	Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	EC₅₀	8.4 μM Compound: Ribavirin	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
MDCK	CC₅₀	58 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 32220685]
MDCK	IC₅₀	98.3 μM Compound: Ribavirin	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay	[PMID: 32520560]
MDCK	CC₅₀	>2130 μM Compound: Ribavirin	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay	[PMID: 33129992]
MDCK	CC₅₀	>2130 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay	[PMID: 33171219]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33328103]
MDCK	CC₅₀	20 μM Compound: Ribavirin	Cytotoxicity against MDCK cells by MTT assay Cytotoxicity against MDCK cells by MTT assay	[PMID: 33705902]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33962311]
MDCK	CC₅₀	>200 μM Compound: Ribavirin	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability Cytotoxicity against dog MDCK cells assessed as reduction in cell viability	[PMID: 34126455]
MDCK	CC₅₀	>50 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34273661]
MDCK	CC₅₀	>300 μM Compound: Ribavirin	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter-Glo assay	[PMID: 36596229]
MDCK	CC₅₀	>100 μM Compound: RBV	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 36764470]
MDCK	CC₅₀	>4095 μM Compound: Ribavirin	Cytotoxicity against MDCK cells infected with influenza A virus California/7/2009(H1N1) Cytotoxicity against MDCK cells infected with influenza A virus California/7/2009(H1N1)	[PMID: 36898483]
MDCK	CC₅₀	>1 mM Compound: Ribavirin	Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1 Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1	[PMID: 37077387]
MDCK	CC₅₀	>1 mM Compound: Ribavirin	Cytotoxicity against dog MDCK cells infected with Influenza A virus H3N2 Cytotoxicity against dog MDCK cells infected with Influenza A virus H3N2	[PMID: 37077387]
MDCK	CC₅₀	>1 mM Compound: Ribavirin	Cytotoxicity against dog MDCK cells infected with Influenza B virus Cytotoxicity against dog MDCK cells infected with Influenza B virus	[PMID: 37077387]
MDCK	CC₅₀	67 μM Compound: Ribavirin	Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay Cytotoxicity against dog MDCK cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter96 Aqueous One Solution cell proliferation assay	[PMID: 37252100]
MDCK	CC₅₀	707.3 μM Compound: RIB	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37517205]
MDCK	CC₅₀	>250 μM Compound: RBV	Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay	[PMID: 39153334]
MDCK	IC₅₀	16.3 μM Compound: Ribavirin	Inhibitory concentration against influenza virus B in MDCK cells Inhibitory concentration against influenza virus B in MDCK cells	[PMID: 7658442]
MDCK	IC₅₀	4.9 μM Compound: Ribavirin	Inhibitory concentration against influenza virus A in MDCK cells Inhibitory concentration against influenza virus A in MDCK cells	[PMID: 7658442]
MDCK	IC₅₀	>200 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line	[PMID: 8246242]
MDCK	IC₅₀	4 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line	[PMID: 8246242]
MDCK	IC₅₀	4 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line	[PMID: 8246242]
MDCK	EC₅₀	3.7 μg/mL Compound: Ribavirin	Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay	[PMID: 9214738]
MDCK	IC₅₀	>200 μg/mL Compound: Ribavirin	Cytotoxicity against MDCK cells by neutral red assay Cytotoxicity against MDCK cells by neutral red assay	[PMID: 9214738]
MDCK	CC₅₀	>100 μg/mL Compound: Ribavirin	The compound was evaluated for cytotoxicity by MTT assay in MDCK cells The compound was evaluated for cytotoxicity by MTT assay in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	11.7 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 yamagata/120/86 strain in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 yamagata/120/86 strain in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	2.1 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 murakami/4/64 strain in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 murakami/4/64 strain in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	2.2 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 Adachi/2/57 in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 Adachi/2/57 in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	34.2 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 Bangkok/10/83 strain in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 Bangkok/10/83 strain in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	5.5 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza B norway/1/80 strain in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza B norway/1/80 strain in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	6.1 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 Philippine/2/82 in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 Philippine/2/82 in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	7.9 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 ishikawa/7/82 in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 ishikawa/7/82 in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	8.3 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 PR8/34 strain in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 PR8/34 strain in MDCK cells	10.1016/S0960-894X(97)10154-8
MDCK	EC₅₀	8.5 μg/mL Compound: Ribavirin	The compound was evaluated for inhibitory effect on the replication of influenza B Singapore/222/79 strain in MDCK cells The compound was evaluated for inhibitory effect on the replication of influenza B Singapore/222/79 strain in MDCK cells	10.1016/S0960-894X(97)10154-8
MOLT-4	IC₅₀	5.7 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line. Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line.	10.1016/0960-894X(96)00216-8
MT4	CC₅₀	31 μM Compound: Ribavirin	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 19482481]
MT4	CC₅₀	31 μM Compound: Ribavirin	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 20359898]
MT4	CC₅₀	31 μM Compound: Ribavirin	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	[PMID: 25082514]
MT4	CC₅₀	31 μM Compound: Ribavirin	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	[PMID: 26443549]
MT4	IC₅₀	>5 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line	[PMID: 8246242]
MT4	IC₅₀	>5 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line	[PMID: 8246242]
MT4	IC₅₀	6.5 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line	[PMID: 8246242]
MT4	IC₅₀	23 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1. Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1.	10.1016/0960-894X(96)00216-8
Raji	IC₅₀	56 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line. Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line.	10.1016/0960-894X(96)00216-8
RD	IC₅₀	60 μg/mL Compound: Ribavirin	Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay	[PMID: 22342145]
RD	CC₅₀	485.9 μg/mL Compound: Ribavirin	Cytotoxicity against human RD cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human RD cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 28858766]
RD	CC₅₀	1485 μM Compound: Ribavirin	Cytotoxicity against human RD cells assessed as reduction in cell viability after 12 hrs by CCK8 assay Cytotoxicity against human RD cells assessed as reduction in cell viability after 12 hrs by CCK8 assay	[PMID: 31063370]
Rhabdomyosarcoma cell	CC₅₀	>500 μg/mL Compound: Ribavirin	Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay	[PMID: 23920438]
SK-OV-3	IC₅₀	10 μg/mL Compound: RBV	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay	[PMID: 31883488]
SK-OV-3	IC₅₀	10 μg/mL Compound: RBV	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay	[PMID: 31883488]
SK-OV-3	IC₅₀	9 μg/mL Compound: RBV	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay	[PMID: 31883488]
SNB-19	CC₅₀	485.2 μM Compound: Ribavirin	Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human SNB-19 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35306290]
SNB-75	IC₅₀	18.53 μM Compound: RBV	Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	[PMID: 31883488]
Vero	EC₅₀	>1600 μM Compound: Ribavirin	Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines	[PMID: 11495586]
Vero	EC₅₀	196 μM Compound: Ribavirin	Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines	[PMID: 11495586]
Vero	EC₅₀	40 μM Compound: Ribavirin	Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines	[PMID: 11495586]
Vero	EC₅₀	40 μM Compound: Ribavirin	Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines	[PMID: 11495586]
Vero	IC₅₀	447.8 μg/mL Compound: RVB	Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells	[PMID: 15603937]
Vero	EC₅₀	119 μM Compound: Ribavirin	Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells	[PMID: 16539402]
Vero	EC₅₀	30 μM Compound: Ribavirin	Inhibition of Rluc-FL-WNV replicon in Vero cells Inhibition of Rluc-FL-WNV replicon in Vero cells	[PMID: 16539402]
Vero	CC₅₀	>500 μM Compound: Ribavirin	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17181162]
Vero	EC₅₀	>500 μM Compound: Ribavirin	Antiviral activity against Sindbis virus in Vero cells Antiviral activity against Sindbis virus in Vero cells	[PMID: 17181162]
Vero	EC₅₀	100 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus in Vero cells Antiviral activity against Punta Toro virus in Vero cells	[PMID: 17181162]
Vero	EC₅₀	100 μM Compound: Ribavirin	Antiviral activity against reovirus 1 in Vero cells Antiviral activity against reovirus 1 in Vero cells	[PMID: 17181162]
Vero	EC₅₀	300 μM Compound: Ribavirin	Antiviral activity against para influenza 3 virus in Vero cells Antiviral activity against para influenza 3 virus in Vero cells	[PMID: 17181162]
Vero	EC₅₀	240 μg/mL Compound: ribavirin	Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	240 μg/mL Compound: ribavirin	Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	48 μg/mL Compound: ribavirin	Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	48 μg/mL Compound: ribavirin	Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	EC₅₀	48 μg/mL Compound: ribavirin	Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 17298047]
Vero	CC₅₀	>850 μM Compound: ribavirin	Cytotoxicity against Vero E6 cells Cytotoxicity against Vero E6 cells	[PMID: 17336519]
Vero	IC₅₀	82 μM Compound: ribavirin	Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay	[PMID: 17336519]
Vero	IC₅₀	0.7 μg/mL Compound: ribavirin	Antiviral activity against Reovirus1 in vero cells Antiviral activity against Reovirus1 in vero cells	[PMID: 17518459]
Vero	IC₅₀	20 μg/mL Compound: ribavirin	Antiviral activity against Punta Toro virus in vero cells Antiviral activity against Punta Toro virus in vero cells	[PMID: 17518459]
Vero	EC₅₀	150 μM Compound: ribavirin	Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	150 μM Compound: ribavirin	Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	250 μM Compound: ribavirin	Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	EC₅₀	50 μM Compound: ribavirin	Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17539622]
Vero	CC₅₀	156 μM Compound: Ribavirin	Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay	[PMID: 17606691]
Vero	EC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	11 μM Compound: Ribavirin	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	13 μM Compound: Ribavirin	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	[PMID: 17606691]
Vero	EC₅₀	>200 μg/mL Compound: ribavirin	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 17948980]
Vero	EC₅₀	120 μg/mL Compound: ribavirin	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	120 μg/mL Compound: ribavirin	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	200 μg/mL Compound: ribavirin	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	40 μg/mL Compound: ribavirin	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	[PMID: 17948980]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
Vero	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
Vero	EC₅₀	45 μg/mL Compound: Ribavirin	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
Vero	CC₅₀	>4100 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay	[PMID: 18955536]
Vero	EC₅₀	28 μM Compound: Ribavirin	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis	[PMID: 18955536]
Vero	EC₅₀	>50 μM Compound: ribavirin	Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
Vero	EC₅₀	>=250 μM Compound: ribavirin	Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
Vero	EC₅₀	146 μM Compound: ribavirin	Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
Vero	EC₅₀	250 μM Compound: ribavirin	Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
Vero	EC₅₀	50 μM Compound: ribavirin	Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
Vero	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
Vero	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
Vero	EC₅₀	>250 μg/mL Compound: ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection	[PMID: 19419804]
Vero	EC₅₀	146 μg/mL Compound: ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
Vero	EC₅₀	45 μg/mL Compound: ribavirin	Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
Vero	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	[PMID: 19482481]
Vero	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	CC₅₀	>250 μM Compound: Ribavirin	Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method	[PMID: 20034711]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	111 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	250 μM Compound: Ribavirin	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	50 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay	[PMID: 20034711]
Vero	EC₅₀	95 μM Compound: Ribavirin	Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	[PMID: 20034711]
Vero	EC₅₀	183 μM Compound: 1	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20207546]
Vero	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	[PMID: 20359898]
Vero	EC₅₀	>400 μg/mL Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	48 μg/mL Compound: Ribavirin	Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	48 μg/mL Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	80 μg/mL Compound: Ribavirin	Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 20377249]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
Vero	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
Vero	EC₅₀	146 μg/mL Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
Vero	EC₅₀	>250 μg/mL Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
Vero	EC₅₀	112 μg/mL Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
Vero	EC₅₀	112 μg/mL Compound: Ribavirin	Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
Vero	EC₅₀	250 μg/mL Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
Vero	EC₅₀	95 μg/mL Compound: Ribavirin	Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
Vero	EC₅₀	18.5 μM Compound: Ribavirin	Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay	[PMID: 21115214]
Vero	IC₅₀	>400 μM Compound: Ribavirin	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 21115214]
Vero	IC₅₀	1690 μM Compound: RBV	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	[PMID: 21441033]
Vero	IC₅₀	2340 μM Compound: RBV	Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	[PMID: 21441033]
Vero	IC₅₀	4090 μM Compound: RBV	Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	[PMID: 21441033]
Vero	IC₅₀	910 μM Compound: RBV	Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	[PMID: 21441033]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
Vero	EC₅₀	>=174 μM Compound: Ribavirin	Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
Vero	EC₅₀	121 μM Compound: Ribavirin	Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
Vero	EC₅₀	125 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity	[PMID: 21565516]
Vero	IC₅₀	2119 μM Compound: RBV	Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis	[PMID: 21880491]
Vero	IC₅₀	910 μM Compound: RBV	Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis	[PMID: 21880491]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
Vero	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
Vero	EC₅₀	29 μM Compound: Ribavirin	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
Vero	EC₅₀	50 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
Vero	EC₅₀	126 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
Vero	EC₅₀	85 μM Compound: Ribavirin	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	[PMID: 22464686]
Vero	IC₅₀	222.2 μM Compound: RBV	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 23734721]
Vero	EC₅₀	>250 μM Compound: ribavirin	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
Vero	EC₅₀	>250 μM Compound: ribavirin	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
Vero	EC₅₀	>250 μM Compound: ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
Vero	EC₅₀	126 μM Compound: ribavirin	Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
Vero	EC₅₀	146 μM Compound: ribavirin	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 23811093]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
Vero	EC₅₀	85 μM Compound: Ribavirin	Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	[PMID: 23911856]
Vero	CC₅₀	8189.67 μM Compound: Ribavirin	Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay	[PMID: 23999140]
Vero	IC₅₀	1576.11 μM Compound: Ribavirin	Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero	IC₅₀	909.96 μM Compound: Ribavirin	Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	[PMID: 23999140]
Vero	IC₅₀	0.9 mM Compound: RBV	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis	[PMID: 24070022]
Vero	IC₅₀	0.9 μM/mL Compound: RBV	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis	[PMID: 24070022]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
Vero	EC₅₀	126 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
Vero	EC₅₀	85 μM Compound: Ribavirin	Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	[PMID: 24312722]
Vero	IC₅₀	253.1 μM Compound: Ribavirin	Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 24679044]
Vero	CC₅₀	>1000 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay	[PMID: 24679044]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	[PMID: 25082514]
Vero	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	[PMID: 25082514]
Vero	IC₅₀	1708 μM Compound: RBV	Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	[PMID: 25699158]
Vero	IC₅₀	1951 μM Compound: RBV	Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	[PMID: 25699158]
Vero	IC₅₀	2101 μM Compound: RBV	Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	[PMID: 25699158]
Vero	IC₅₀	694.6 μM Compound: RBV	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	[PMID: 25699158]
Vero	IC₅₀	910.8 μM Compound: RBV	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	[PMID: 25699158]
Vero	CC₅₀	>410 μM Compound: Ribavirin	Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay	[PMID: 25791449]
Vero	EC₅₀	47.9 μM Compound: Ribavirin	Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay	[PMID: 25791449]
Vero	EC₅₀	35 μM Compound: Ribavirin	Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	[PMID: 26001344]
Vero	CC₅₀	409 μM Compound: ribavirin	Cytotoxicity against african green monkey Vero B cells Cytotoxicity against african green monkey Vero B cells	[PMID: 26039671]
Vero	EC₅₀	42 μM Compound: ribavirin	Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis	[PMID: 26039671]
Vero	IC₅₀	1200 μM Compound: ribavirin	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 26110443]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
Vero	EC₅₀	250 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
Vero	EC₅₀	85 μM Compound: Ribavirin	Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	[PMID: 26114811]
Vero	IC₅₀	1197.58 μM Compound: RBV	Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption	[PMID: 26132528]
Vero	IC₅₀	26.7 μM Compound: ribavirin	Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay	[PMID: 26260336]
Vero	IC₅₀	37.3 μM Compound: ribavirin	Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay	[PMID: 26260336]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	[PMID: 26291038]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	[PMID: 26291038]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	[PMID: 26291038]
Vero	EC₅₀	150 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	[PMID: 26291038]
Vero	EC₅₀	73.5 μM Compound: Ribavirin	Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	[PMID: 26291038]
Vero	EC₅₀	13.5 μM Compound: RIBA	Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique	[PMID: 26638041]
Vero	CC₅₀	0.3 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero E6 cells Cytotoxicity against African green monkey Vero E6 cells	[PMID: 27262598]
Vero	IC₅₀	0.04 μM Compound: Ribavirin	Antiviral activity against Hepatitis C virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against Hepatitis C virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect	[PMID: 27262598]
Vero	IC₅₀	10 μM Compound: Ribavirin	Antiviral activity against Herpes simplex virus type 1 L2 infected in African green monkey Vero E6 cells assessed as reduction of virus-induced cytopathic effect Antiviral activity against Herpes simplex virus type 1 L2 infected in African green monkey Vero E6 cells assessed as reduction of virus-induced cytopathic effect	[PMID: 27262598]
Vero	IC₅₀	>500 μM Compound: RBV	Antiviral activity against Coxsackievirus B2 Ohio-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B2 Ohio-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27750147]
Vero	IC₅₀	>500 μM Compound: RBV	Antiviral activity against Coxsackievirus B4 JVB infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B4 JVB infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27750147]
Vero	IC₅₀	2088 μM Compound: RBV	Antiviral activity against Coxsackievirus B6 Schmitt infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B6 Schmitt infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27750147]
Vero	IC₅₀	2375 μM Compound: RBV	Antiviral activity against Coxsackievirus B1 Conn 5 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B1 Conn 5 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27750147]
Vero	IC₅₀	3316 μM Compound: RBV	Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27750147]
Vero	IC₅₀	379.1 μM Compound: RBV	Antiviral activity against Coxsackievirus B3 Nancy infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B3 Nancy infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27750147]
Vero	IC₅₀	292 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27792321]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	EC₅₀	50 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	[PMID: 27979594]
Vero	IC₅₀	>40948 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B2 (strain Ohio-1) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus B2 (strain Ohio-1) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	IC₅₀	>40948 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B4 J.V.B infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus B4 J.V.B infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	IC₅₀	2088 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	IC₅₀	2375 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	IC₅₀	3316 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	IC₅₀	379.12 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	IC₅₀	9622 μM Compound: Ribavirin	Antiviral activity against Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis Antiviral activity against Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	[PMID: 28109785]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	EC₅₀	29 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	[PMID: 28477572]
Vero	CC₅₀	1622 μM Compound: 95	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 28689975]
Vero	IC₅₀	38.49 μg/mL Compound: RBV	Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis	[PMID: 30578076]
Vero	CC₅₀	>400 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30612844]
Vero	EC₅₀	18.5 μM Compound: Ribavirin	Antiviral activity against Junin virus IV4454 infected in African green monkey Vero cells assessed as reduction in vrius yield after 48 hrs by plaque assay Antiviral activity against Junin virus IV4454 infected in African green monkey Vero cells assessed as reduction in vrius yield after 48 hrs by plaque assay	[PMID: 30612844]
Vero	EC₅₀	95 μM Compound: Ribavirin	Antiviral activity against West Nile virus infected in African green monkey Vero cells incubated for 4 days by crystal violet staining based plaque reduction assay Antiviral activity against West Nile virus infected in African green monkey Vero cells incubated for 4 days by crystal violet staining based plaque reduction assay	[PMID: 30721061]
Vero	EC₅₀	12 μg/mL Compound: Ribavirin	Antiviral activity against Pichinde virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect Antiviral activity against Pichinde virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect	[PMID: 31431358]
Vero	EC₅₀	9.3 μg/mL Compound: Ribavirin	Antiviral activity against Tacaribe virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect Antiviral activity against Tacaribe virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect	[PMID: 31431358]
Vero	CC₅₀	>100 μM Compound: 9	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 31549836]
Vero	EC₅₀	20.8 μM Compound: 9	Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity after 72 hrs by DAPI staining based assay Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity after 72 hrs by DAPI staining based assay	[PMID: 31549836]
Vero	IC₅₀	884.9 μM Compound: Ribavirin	Antiviral activity against CVB3 infected in African green monkey Vero cells by MTT assay Antiviral activity against CVB3 infected in African green monkey Vero cells by MTT assay	[PMID: 31735601]
Vero	CC₅₀	297 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 31843348]
Vero	EC₅₀	2.42 μM Compound: Ribavirin	Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection	[PMID: 31843348]
Vero	EC₅₀	3.95 μM Compound: Ribavirin	Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection	[PMID: 31843348]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
Vero	EC₅₀	112 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
Vero	EC₅₀	50 μM Compound: Ribavirin	Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
Vero	IC₅₀	13.3 μM Compound: Ribavirin	Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect by CCK-8 assay Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect by CCK-8 assay	[PMID: 32937282]
Vero	IC₅₀	13.3 μM Compound: Ribavirin	Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect incubated for 72 to 96 hrs by CCK-8 assay Antiviral activity against human EV71 infected in African green monkey Vero cells assessed as reduction in cytopathic effect incubated for 72 to 96 hrs by CCK-8 assay	[PMID: 32937282]
Vero	CC₅₀	>400 μM Compound: 73	Cytotoxicity against African green monkey Vero cells by CCK8 assay method Cytotoxicity against African green monkey Vero cells by CCK8 assay method	[PMID: 33070079]
Vero	CC₅₀	300 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells by MTT assay Cytotoxicity against African green monkey Vero cells by MTT assay	[PMID: 33822611]
Vero	CC₅₀	470.5 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35306290]
Vero	CC₅₀	1245 μM Compound: RBV	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTS assay	[PMID: 35661850]
Vero	CC₅₀	>3562 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by neutral red dye based analysis Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by neutral red dye based analysis	[PMID: 36898483]
Vero	CC₅₀	>4094 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by visual analysis Cytotoxicity against African green monkey Vero cells infected in Pichinde virus AN 4763 by visual analysis	[PMID: 36898483]
Vero	CC₅₀	>4094 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by visual analysis Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by visual analysis	[PMID: 36898483]
Vero	CC₅₀	3931 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by neutral red dye based analysis Cytotoxicity against African green monkey Vero cells infected with Tacaribe virus TRVL11573 by neutral red dye based analysis	[PMID: 36898483]
Vero	ED₅₀	9.0 x 10^-5 M Compound: 3	In vitro antiviral activity against vaccinia virus in Vero cells. In vitro antiviral activity against vaccinia virus in Vero cells.	[PMID: 3950908]
Vero	ED₅₀	9.9 x 10^-5 M Compound: 3	In vitro antiviral activity against measles virus in Vero cells In vitro antiviral activity against measles virus in Vero cells	[PMID: 3950908]
Vero	ED₅₀	0.00016 M Compound: 3	In vitro antiviral activity against parainfluenza type 3 virus in Vero cells. In vitro antiviral activity against parainfluenza type 3 virus in Vero cells.	[PMID: 3950908]
Vero	ED₅₀	0.00019 M Compound: 3	In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells. In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells.	[PMID: 3950908]
Vero	ED₅₀	0.16 mM Compound: 3	In vitro antiviral activity against parainfluenza type 3 virus in Vero cells. In vitro antiviral activity against parainfluenza type 3 virus in Vero cells.	[PMID: 3950908]
Vero	ED₅₀	0.19 mM Compound: 3	In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells. In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells.	[PMID: 3950908]
Vero	ED₅₀	3.3 x 10^-5 M Compound: Ribavirin	In vitro antiviral activity against measles virus was evaluated. In vitro antiviral activity against measles virus was evaluated.	[PMID: 4020823]
Vero	ED₅₀	8.5 x 10^-5 M Compound: Ribavirin	In vitro antiviral activity against vaccinia virus was evaluated. In vitro antiviral activity against vaccinia virus was evaluated.	[PMID: 4020823]
Vero	ED₅₀	0.00016 M Compound: Ribavirin	In vitro antiviral activity against Parainfluenza type 3 was evaluated. In vitro antiviral activity against Parainfluenza type 3 was evaluated.	[PMID: 4020823]
Vero	ED₅₀	0.00019 M Compound: Ribavirin	In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated. In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.	[PMID: 4020823]
Vero	ED₅₀	0.16 mM Compound: Ribavirin	In vitro antiviral activity against Parainfluenza type 3 was evaluated. In vitro antiviral activity against Parainfluenza type 3 was evaluated.	[PMID: 4020823]
Vero	ED₅₀	0.19 mM Compound: Ribavirin	In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated. In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.	[PMID: 4020823]
Vero	IC₅₀	286.8 μM Compound: Ribavirin	Inhibitory concentration against parainfluenza-3 virus in vero cells Inhibitory concentration against parainfluenza-3 virus in vero cells	[PMID: 7658442]
Vero	IC₅₀	>400 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus cell morphology in Vero cell line Tested for inhibitory effect on RNA virus cell morphology in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	>=235 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus SFV in Vero cell line Tested for inhibitory effect on RNA virus SFV in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	>=250 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus SV in Vero cell line Tested for inhibitory effect on RNA virus SV in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	160 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	20 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	20 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus PV-3 in Vero cell line Tested for inhibitory effect on RNA virus PV-3 in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	5.2 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus JV in Vero cell line Tested for inhibitory effect on RNA virus JV in Vero cell line	[PMID: 8246242]
Vero	IC₅₀	6.4 μg/mL Compound: ribavirin	Tested for inhibitory effect on RNA virus TV in Vero cell line Tested for inhibitory effect on RNA virus TV in Vero cell line	[PMID: 8246242]
Vero	CC₅₀	>400 μg/mL Compound: ribavirin	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells	[PMID: 8709116]
Vero	EC₅₀	>1600 μM Compound: d	concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells	[PMID: 9748360]
Vero	EC₅₀	64 μM Compound: d	concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells	[PMID: 9748360]
Vero	EC₅₀	64 μM Compound: d	concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells	[PMID: 9748360]
Vero	EC₅₀	64 μM Compound: d	concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells	[PMID: 9748360]
Vero	EC₅₀	64 μM Compound: d	concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells	[PMID: 9748360]
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Mammalian orthoreovirus 1 virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Mammalian orthoreovirus 1 virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
Vero	EC₅₀	>250 μM Compound: Ribavirin	Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
Vero	EC₅₀	146 μM Compound: Ribavirin	Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
Vero	EC₅₀	45 μM Compound: Ribavirin	Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
Vero 76	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	[PMID: 19482481]
Vero 76	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	[PMID: 19482481]
Vero 76	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	[PMID: 25082514]
Vero 76	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	>1000 μM Compound: ribavirin	Cytotoxicity against African green monkey Vero 76 cells relative to control Cytotoxicity against African green monkey Vero 76 cells relative to control	[PMID: 26260336]
Vero 76	CC₅₀	>1000 μM Compound: ribavirin	Cytotoxicity against African green monkey Vero 76 cells Cytotoxicity against African green monkey Vero 76 cells	[PMID: 26260336]
Vero 76	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	>100 μM Compound: Ribavirin	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	7 μM Compound: Ribavirin	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	>100 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	EC₅₀	1.2 μM Compound: Ribavirin	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay	[PMID: 29028528]
Vero 76	CC₅₀	>4094 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by neutral red dye based analysis Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by neutral red dye based analysis	[PMID: 36898483]
Vero 76	CC₅₀	>4094 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by visual analysis Cytotoxicity against African green monkey Vero 76 cells infected with Rift Valley fever virus MP-12 by visual analysis	[PMID: 36898483]
Vero C1008	IC₅₀	1024 μM Compound: Ribavirin	Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	1024 μM Compound: Ribavirin	Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	1024 μM Compound: Ribavirin	Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	1024 μM Compound: Ribavirin	Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	1024 μM Compound: Ribavirin	Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	512 μM Compound: Ribavirin	Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 28408228]
Vero C1008	IC₅₀	125 μg/mL Compound: Ribavirin	Antiviral activity against Human herpesvirus 1 L2 infected in African green monkey Vero E6 cells assessed as protection against virus-induced cytopathic effect Antiviral activity against Human herpesvirus 1 L2 infected in African green monkey Vero E6 cells assessed as protection against virus-induced cytopathic effect	[PMID: 29173944]
Vero C1008	CC₅₀	>100 μM Compound: RBV	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability	[PMID: 31902708]
Vero C1008	EC₅₀	33 μM Compound: RBV	Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in viral induced cytopathic effect Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in viral induced cytopathic effect	[PMID: 31902708]
Vero C1008	CC₅₀	>200 μM Compound: Ribavirin	Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability	[PMID: 32378892]
Vero C1008	EC₅₀	33 μM Compound: Ribavirin	Antiviral activity against Zika virus infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 96 hrs by CCK8 assay Antiviral activity against Zika virus infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 96 hrs by CCK8 assay	[PMID: 32378892]
Vero C1008	CC₅₀	>400 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay	[PMID: 32511912]
Vero C1008	CC₅₀	>400 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	CC₅₀	>400 μM Compound: 5	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	[PMID: 32845145]
Vero C1008	CC₅₀	>400 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as cell growth inhibition measured after 48 hrs by CCK-8 assay	[PMID: 32992245]
Vero C1008	CC₅₀	>400 μM Compound: 53	Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay	[PMID: 33486200]
Vero C1008	EC₅₀	109.5 μM Compound: 53	Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay Antiviral activity against SARS-CoV infected in Vero E6 cells assessed as reduction in viral replication measured after 48 hrs by qRT-PCR assay	[PMID: 33486200]
Vero C1008	CC₅₀	>400 μM Compound: Ribavirin	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	[PMID: 34273661]
Vero C1008	CC₅₀	>160 μM Compound: R	Cytotoxicity against African green monkey Vero E6 cells infected with Zika 459148 measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells infected with Zika 459148 measured after 72 hrs by MTT assay	[PMID: 35969814]
Vero C1008	CC₅₀	>160 μM Compound: R	Cytotoxicity against African green monkey Vero E6 cells infected with ZIKV COL345Si measured after 6 days by MTT assay Cytotoxicity against African green monkey Vero E6 cells infected with ZIKV COL345Si measured after 6 days by MTT assay	[PMID: 35969814]
WIL2-NS	IC₅₀	>100 μM Compound: Ribavirin	Compound was tested for its effect on the proliferation of WIL-2-NS cell line. Compound was tested for its effect on the proliferation of WIL-2-NS cell line.	10.1016/0960-894X(96)00216-8

In Vitro

Treatment of LPS-stimulated microglia with 5, 10 and 20 μM Ribavirin (ICN-1229) induces reduction of NO₂ levels for 43% (p<0.05), 53% (p<0.05) and 59% (p<0.05), respectively. Ribavirin (ICN-1229) (10 mM) insignificantly decreases the cell surface area in non-stimulated culture, but significantly reduces cell surface area (by 32%, p<0.05) in LPS-stimulated microglia^[3]. Ribavirin (ICN-1229) is active against DENV, with an EC₅₀ of 3 μM in A549 cells, and combination of CM-10-18 with Ribavirin (ICN-1229) demonstrates a clear enhancement in the reduction of virus replication^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ALT, AST activities and bilirubin levels are significantly loared by administration of JAT in combination with interferon and Ribavirin (ICN-1229) (p<0.01). JAT, interferon or ribavirin alone with CCl₄, livers appear to exhibit some liver protection against CCl₄ as evident by the presence of normal hepatic cords, absence of necrosis and lesser fatty infiltration. Groups treated with JAT, Peg-interferon and Ribavirin (ICN-1229) separately or in combination shows reduction in the expression of TGF- β and Bax. In the group treated by triple combination of interferon, Ribavirin (ICN-1229), and JAT, the expression level of p53 is markedly reduced^[1].
Ribavirin (ICN-1229) capsules (400 mg of ribavirin)-treated Wistar rats show a significant decrease in activin-A and significant increase in follistatin at the serum and liver levels. Ribavirin (ICN-1229) has strong antiviral activity only when ribavirin is combined with either IFN-α or Peg-IFN-α^[2].
Ribavirin (40 mg/kg, p.o.) significantly improves the antiviral efficacy of CM-10-18 in mice. Ribavirin (ICN-1229) inhibits DENV virus infection in cultured cells, but it is ineffective in reducing viremia in monotherapy^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 36791-04-5
Appearance Solid
Molecular Weight 244.20
Formula C₈H₁₂N₄O₅
Color White to off-white
SMILES

O[C@H]1[C@@H](O)[C@H](N2N=C(C(N)=O)N=C2)O[C@@H]1CO
Synonyms

Ribasphere
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (56)

All Cell Proliferation/Viability AssayIFWBIHCRT-PCR

Sort by:

Journal Impact Factor

Nat Commun

A mouse-adapted Yezo virus model for antiviral testing in immunocompetent mice. [Abstract]

2026 Mar 17;17(1):4058. PMID: 41844638
Nano Lett

Nanopore Signatures of Nucleoside Drugs. [Abstract]

2023 Oct 25;23(20):9437-9444. PMID: 37818841
J Pharm Anal

2025 Apr 12.

Ribavirin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Apr 12.

Viability of A549 cells following treatment with 10 μM Ribavirin or the control for 1–5 days.

Ribavirin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Apr 12.

Ribavirin (10 μg/mL; 0-24 h). Immunoblotting of phosphorylated AMPK (p-AMPK) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the lysates of mouse Lewis lung carcinoma (LLC) cells in the presence of Ribavirin.

Ribavirin purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Apr 12.

Ribavirin (10 μM; 0-24 h). Quantitative real-time polymerase chain reaction (qRT-PCR) measurement of 4ebp1 transcripts in LLC cells in the presence of phosphate buffered saline (PBS) or the indicated concentrations of Ribavirin.
Phytomedicine

Procyanidins inhibit alphacoronavirus infection by reducing interferon antagonism. [Abstract]

2025 May:140:156549. PMID: 40023969
BMC Med

Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. [Abstract]

2020 Jul 31;18(1):204. PMID: 32731873
Int J Radiat Oncol Biol Phys

Targeting Phosphatidylinositol 4-Kinase IIIα for Radiosensitization: A Potential Model of Drug Repositioning Using an Anti-Hepatitis C Viral Agent. [Abstract]

2016 Nov 15;96(4):867-876. PMID: 27788957
Eur J Med Chem

Design, synthesis, and biological evaluation of novel 2'-methyl-2'-fluoro-6-methyl-7-alkynyl-7-deazapurine nucleoside analogs as anti-Zika virus agents. [Abstract]

2022 Apr 15:234:114275. PMID: 35306290
Eur J Med Chem

System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. [Abstract]

2021 Nov 15:224:113683. PMID: 34273661
Pharm Biol

XiaoEr LianHuaQinqGan alleviates viral pneumonia in mice infected by influenza A and respiratory syncytial viruses. [Abstract]

2022 Dec;60(1):2355-2366. PMID: 36444944
mBio

Respiratory syncytial virus co-opts hypoxia-inducible factor-1α-mediated glycolysis to favor the production of infectious virus. [Abstract]

2023 Oct 31;14(5):e0211023. PMID: 37796013

Ribavirin purchased from MedChemExpress. Usage Cited in: mBio. 2023 Oct 31;14(5):e0211023. [Abstract]

Ribavirin (40 mg/kg; po). The RSV F protein level in the lung tissues of each group were determined using immunofluorescence assay.

Ribavirin purchased from MedChemExpress. Usage Cited in: mBio. 2023 Oct 31;14(5):e0211023. [Abstract]

Ribavirin (40 mg/kg; po). Histopathological analysis of lung tissues in each group was performed using hematoxylin-eosin staining. Black arrow indicates the pulmonary infiltration of inflammatory cells.
J Med Virol

Bergamottin, A Natural Bioactive Compound, Inhibits Dabie Bandavirus Infection In Vitro and In Vivo. [Abstract]

2025 Jul;97(7):e70495. PMID: 40673712
Molecules

Dapoxetine, a Selective Serotonin Reuptake Inhibitor, Suppresses Zika Virus Infection In Vitro. [Abstract]

2023 Dec 17;28(24):8142. PMID: 38138628
Hepatol Commun

Genotype 5 Hepatitis E Virus Produced by a Reverse Genetics System Has the Potential for Zoonotic Infection. [Abstract]

2018 Nov 30;3(1):160-172. PMID: 30620002
Front Microbiol

Emodin inhibits respiratory syncytial virus entry by interactions with fusion protein. [Abstract]

2024 May 16:15:1393511. PMID: 38817970
Front Microbiol

Reverse Genetic Approaches for the Generation of Full Length and Subgenomic Replicon of EV71 Virus. [Abstract]

2021 May 20;12:665879. PMID: 34093481
Antimicrob Agents Chemother

Inhibitory Effect of PIK-24 on Respiratory Syncytial Virus Entry by Blocking Phosphatidylinositol-3 Kinase Signaling. [Abstract]

2020 Sep 21;64(10):e00608-20. PMID: 32718963
Appl Microbiol Biotechnol

The commercial PRRSV attenuated vaccine can be a potentially effective live trivalent vaccine vector. [Abstract]

2025 May 2;109(1):109. PMID: 40316839
BMC Microbiol

6-thioguanine inhibits EV71 replication by reducing BIRC3-mediated autophagy. [Abstract]

2025 Jan 29;25(1):53. PMID: 39881250
Microorganisms

In Silico Identification and In Vitro Validation of Repurposed Compounds Targeting the RSV Polymerase. [Abstract]

2023 Jun 18;11(6):1608. PMID: 37375110
Antiviral Res

High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay. [Abstract]

2025 Aug:240:106209. PMID: 40484321
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635
Antiviral Res

Effectiveness of nucleoside analogs against Wetland virus infection. [Abstract]

2025 Apr:236:106114. PMID: 39954869
Antiviral Res

Metformin inhibits EV-A71 and CVA16 infections by regulating TRIB3-SCARB2 axis and activating AMPK. [Abstract]

2025 Jan 16:235:106081. PMID: 39826812
Antiviral Res

Favipiravir and Ribavirin protect immunocompetent mice from lethal CCHFV infection. [Abstract]

2023 Oct:218:105703. PMID: 37611878
Antiviral Res

Antiviral effect of vesatolimod (GS-9620) against foot-and-mouth disease virus both in vitro and invivo. [Abstract]

2022 Sep:205:105384. PMID: 35863499
Antiviral Res

Advancing Marburg virus antiviral screening: Optimization of a novel T7 polymerase-independent minigenome system. [Abstract]

2021 Jan;185:104977. PMID: 33220335
Antiviral Res

Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system. [Abstract]

2018 Jun:154:51-57. PMID: 29653132
J Virol

DIDS modulates VDAC1 oligomerization to suppress intrinsic apoptosis and attenuates in vitro and in vivo RSV infection. [Abstract]

2026 Mar 24;100(3):e0220025. PMID: 41670372
ACS Infect Dis

Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]

2025 Oct 30. PMID: 41166549
ACS Infect Dis

Development of a Universal Type A Influenza Viral RdRp-Induced Reporter System with Potential for Antiviral Drug Screening. [Abstract]

2025 Jun 13;11(6):1437-1447. PMID: 40421776
J Virol

PIK-24 Inhibits RSV-Induced Syncytium Formation via Direct Interaction with the p85α Subunit of PI3K. [Abstract]

2022 Dec 14;96(23):e0145322. PMID: 36416586
Heliyon

Network pharmacology associated anti-influenza mechanism research of Qingjie-Tuire Granule via STAT1/3 signaling pathway. [Abstract]

2023 Mar 20;9(3):e14649. PMID: 37101493
Viruses

Bergamottin Inhibits Bovine Viral Diarrhea Virus Replication by Suppressing ROS-Mediated Endoplasmic Reticulum Stress and Apoptosis. [Abstract]

2024 Aug 13;16(8):1287. PMID: 39205261
Vet Res

The natural compound Sanggenon C inhibits PRRSV infection by regulating the TRAF2/NF-κB signalling pathway. [Abstract]

2023 Nov 30;54(1):114. PMID: 38037100
Viruses

Repurposing of Doramectin as a New Anti-Zika Virus Agent. [Abstract]

2023 Apr 27;15(5):1068. PMID: 37243154
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Front Oncol

Gut virome dysbiosis impairs antitumor immunity and reduces 5-fluorouracil treatment efficacy for colorectal cancer. [Abstract]

2024 Dec 19:14:1501981. PMID: 39791120
Virus Res

Venenum bufonis and its active constituents alleviate RSV-induced pneumonia in mice by suppressing macrophage infiltration and NLRP3 inflammasome activation. [Abstract]

2026 Jan:363:199672. PMID: 41349590
SLAS Discov

High-Throughput cell-based immunofluorescence assays against influenza. [Abstract]

2024 Jan;29(1):66-76. PMID: 37925159
Adv Biol (Weinh)

The Common Immune Responses Differences from Transcriptomic Profiling in Cardiomyocytes upon Coxsackievirus B5 and Echovirus 6 Infection. [Abstract]

2026 Feb;10(2):e00281. PMID: 41705593
Virology

Theaflavins suppresses RSV infection by modulating the MAVS-I-IFN pathway. [Abstract]

2026 Jun:619:110872. PMID: 41864138
Virology

BCX4430 inhibits the replication of rabies virus by suppressing mTOR-dependent autophagy invitro. [Abstract]

2023 Aug:585:21-31. PMID: 37267717
Virology

The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir. [Abstract]

2019 Oct:536:58-67. PMID: 31400550
J Virol Methods

Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin. [Abstract]

2021 Dec:298:114283. PMID: 34534610
SSRN

2026 Mar 7.
Res Sq

2025 Dec 18.
bioRxiv

2025 August 15.
bioRxiv

2025 Jan 06.
bioRxiv

2025 January 29.
Res Sq

2024 Jun 19.
Research Square Preprint

2023 Oct 12.
Research Square Preprint

2021 Oct.
Research Square Preprint

2021 Aug.
Universidade de São Paulo

2020 Sep.
Seoul National University

2016 Aug.

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (409.50 mM; Need ultrasonic)

DMSO : 100 mg/mL (409.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0950 mL

20.4750 mL

40.9500 mL

5 mM

0.8190 mL

4.0950 mL

8.1900 mL

10 mM

0.4095 mL

2.0475 mL

4.0950 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 110 mg/mL (450.45 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocol

Cell Assay^[3]

The effect of Ribavirin (ICN-1229) on microglial cell viability is evaluated by the sulforhodamine B (SRB) chemosensitivity assay. Briefly, LPS-stimulated microglial cells are incubated for 48 h in the presence or absence of Ribavirin (ICN-1229). Afterward, the cells are fixed in 10% (w/v) trichloroacetic acid for 1 h at 4°C, rinsed in tap water and stained with 0.4% (w/v) SRB in 1% acetic acid (100 μL/well) for 30 min at room temperature (RT). The cells are then rinsed three times in 1% acetic acid to remove the unbound stain. The protein bound stain is extracted with 200 μL 10 mM Tris base (pH 10.5) per well. The optical density is read at 540 nm, with correction at 670 nm. The results are presented as percentage of the control (non-stimulated/untreated microglial cells), that is arbitrarily set to 100%.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

The in vivo efficacy experiments are largely performed, using a dengue viremia model in AG129 mouse (defective of both type I and type II interferon receptors). Each experiment contains 6 mice (7 to 8 week-old) per dosing group. The mice are challenged with DENV (serotype 2, TSV01 strain), at 5×10⁶ pfu/mouse via i.p. injection. Imino sugars are dosed twice daily at 12 hr intervals, and ribavirin is dosed once daily, for 3 consecutive days post-infection. Blood samples are drawn 3 days post-infection for determination of plasma virus titer by plaque assay.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Portuguese - PT (418 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Abdel-Hamid NM, et al. Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats. Asian Pac J Cancer Prev. 2016;17(4):1979-85. [Content Brief]

[2]. Refaat B, et al. The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Res Notes. 2015 Jun 26;8:265 [Content Brief]

[3]. Savic D, et al. Ribavirin shows immunomodulatory effects on activated microglia. Immunopharmacol Immunotoxicol. 2014 Dec;36(6):433-41 [Content Brief]

[4]. Chang J, et al. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011 Jan;89(1):26-34 [Content Brief]

[5]. Robert O Baker, et al. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003 Jan;57(1-2):13-23. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	4.0950 mL	20.4750 mL	40.9500 mL	102.3751 mL
	5 mM	0.8190 mL	4.0950 mL	8.1900 mL	20.4750 mL
	10 mM	0.4095 mL	2.0475 mL	4.0950 mL	10.2375 mL
	15 mM	0.2730 mL	1.3650 mL	2.7300 mL	6.8250 mL
	20 mM	0.2048 mL	1.0238 mL	2.0475 mL	5.1188 mL
	25 mM	0.1638 mL	0.8190 mL	1.6380 mL	4.0950 mL
	30 mM	0.1365 mL	0.6825 mL	1.3650 mL	3.4125 mL
	40 mM	0.1024 mL	0.5119 mL	1.0238 mL	2.5594 mL
	50 mM	0.0819 mL	0.4095 mL	0.8190 mL	2.0475 mL
	60 mM	0.0683 mL	0.3413 mL	0.6825 mL	1.7063 mL
	80 mM	0.0512 mL	0.2559 mL	0.5119 mL	1.2797 mL
	100 mM	0.0410 mL	0.2048 mL	0.4095 mL	1.0238 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ribavirin

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Nucleotide Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Anti-Hepatitis C Virus Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Orthopoxvirus Compound Library

Off-patent Drug Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Ribavirin

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (56)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ribavirin Related Classifications

Cat. No.: HY-B0434